Insider Selling: Kestra Medical Technologies (NASDAQ:KMTS) Insider Sells $342,000.00 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $22.80, for a total transaction of $342,000.00. Following the completion of the sale, the insider directly owned 394,786 shares of the company’s stock, valued at approximately $9,001,120.80. This trade represents a 3.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $26.59, for a total transaction of $398,850.00.

Kestra Medical Technologies Stock Up 4.7%

NASDAQ KMTS opened at $24.71 on Friday. Kestra Medical Technologies, Ltd. has a twelve month low of $13.25 and a twelve month high of $30.00. The stock has a market cap of $1.44 billion and a PE ratio of -7.79. The firm has a 50-day simple moving average of $25.47 and a 200 day simple moving average of $22.24. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47.

Institutional Investors Weigh In On Kestra Medical Technologies

Several large investors have recently made changes to their positions in KMTS. Alliancebernstein L.P. lifted its holdings in Kestra Medical Technologies by 13.7% during the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after acquiring an additional 785,557 shares during the last quarter. Brown Advisory Inc. boosted its holdings in shares of Kestra Medical Technologies by 5.4% in the 2nd quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after acquiring an additional 29,607 shares in the last quarter. Millennium Management LLC bought a new stake in Kestra Medical Technologies during the 1st quarter worth approximately $11,036,000. Finally, Franklin Resources Inc. increased its holdings in Kestra Medical Technologies by 32.4% during the 2nd quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock valued at $7,318,000 after purchasing an additional 108,103 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research note on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. The Goldman Sachs Group set a $24.00 target price on shares of Kestra Medical Technologies in a research note on Friday, January 16th. Finally, Piper Sandler raised their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.